Quantification of Cerebral Nicotinic Acetylcholine Receptors by PET Using 2-[18F]Fluoro-A-85380 and the Multiinjection Approach
暂无分享,去创建一个
Jean-Dominique Gallezot | André Syrota | Marie-Claude Grégoire | Frédéric Dollé | Françoise Hinnen | M. Grégoire | J. Gallezot | J. Delforge | A. Syrota | F. Dollé | H. Valette | M. Bottlaender | F. Hinnen | C. Coulon | Michel A Bottlaender | Jacques Delforge | Héric Valette | Wadad Saba | Christine M Coulon | Michèle P Ottaviani | M. Ottaviani | W. Saba
[1] N. Alpert,et al. Concentration of dopamine transporters: To Bmax or not to Bmax? , 1999, Synapse.
[2] V. O. Wagner,et al. Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography , 2005, Journal of Pharmacology and Experimental Therapeutics.
[3] Karmen K. Yoder,et al. Estimation of local receptor density, B'max, and other parameters via multiple-injection positron emission tomography experiments. , 2004, Methods in enzymology.
[4] C. Gotti,et al. Neuronal nicotinic receptors: from structure to pathology , 2004, Progress in Neurobiology.
[5] A. Sato,et al. Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats , 1997, Neuroscience Letters.
[6] Yu-Shin Ding,et al. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region. , 2005, Nuclear medicine and biology.
[7] R H Huesman,et al. Dynamic PET Data Analysis , 1986, Journal of computer assisted tomography.
[8] James V. Beck,et al. Parameter Estimation in Engineering and Science , 1977 .
[9] A. Syrota,et al. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. , 1984, Life sciences.
[10] A. Nordberg,et al. Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres , 1989, Neuroscience Letters.
[11] E. Perry,et al. Molecular analysis of nicotinic receptor expression in autism. , 2004, Brain research. Molecular brain research.
[12] D E Kuhl,et al. Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] Bernard Bendriem,et al. Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium Approaches , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[14] K. B. Larson,et al. Strategies for in vivo Measurement of Receptor Binding Using Positron Emission Tomography , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] Felix Franks,et al. In-Vitro Characterization of mCerulean3_mRuby3 as a Novel FRET Pair with Favorable Bleed-Through Characteristics , 2019, Biosensors.
[16] S. Potkin,et al. Synthesis and Evaluation of Nicotine 42 Receptor Radioligand, 5-(3- 18 F-Fluoropropyl)-3- (2-(S)-Pyrrolidinylmethoxy)Pyridine, in Rodents and PET in Nonhuman Primate , 2005 .
[17] R. Waterhouse,et al. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[18] R. Egleton,et al. Modulation of cerebral microvascular permeability by endothelial nicotinic acetylcholine receptors. , 2005, American journal of physiology. Heart and circulatory physiology.
[19] A. Saija,et al. Modifications of the permeability of the blood-brain barrier and local cerebral metabolism in pentobarbital- and ketamine-anaesthetized rats , 1989, Neuropharmacology.
[20] M Slifstein,et al. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. , 2001, Nuclear medicine and biology.
[21] A. Nordberg,et al. Autoradiographic comparison of [3H](−)nicotine, [3H]cytisine and [3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease , 1999, Neuroscience.
[22] C. Crouzel,et al. Synthesis of 2‐[18F]fluoro‐3‐[2(S)‐2‐azetidinylmethoxy]pyridine, a highly potent radioligand for in vivo imaging central nicotinic acetylcholine receptors , 1998 .
[23] S. Arneric,et al. Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats. , 1993, The Journal of pharmacology and experimental therapeutics.
[24] A. Nordberg,et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors , 2000, Behavioural Brain Research.
[25] E. Perry,et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380. , 2004, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[26] B. Mazoyer,et al. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. , 1990, Circulation.
[27] M E Phelps,et al. Neuroreceptor Assay with Positron Emission Tomography: Equilibrium versus Dynamic Approaches , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[28] C Crouzel,et al. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. , 1999, Journal of medicinal chemistry.
[29] O. Steinlein. Nicotinic acetylcholine receptors and epilepsy. , 2002, Current drug targets. CNS and neurological disorders.
[30] David J. Schlyer,et al. Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] L. Farde,et al. Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[32] Agneta Nordberg,et al. Neuronal nicotinic receptors in the human brain , 2000, Progress in Neurobiology.
[33] N. Volkow,et al. Effects of Blood Flow on [11C]Raclopride Binding in the Brain: Model Simulations and Kinetic Analysis of PET Data , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[34] E. Eger. The pharmacology of isoflurane. , 1984, British journal of anaesthesia.
[35] Agneta Nordberg,et al. [3H]Acetylcholine nicotinic recognition sites in human brain: Characterization of agonist binding , 1987, Neuroscience Letters.
[36] J. Links,et al. 6-[18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. , 2000, Life sciences.
[37] Paul A. Viola,et al. Alignment by Maximization of Mutual Information , 1997, International Journal of Computer Vision.
[38] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[39] Jean-Dominique Gallezot,et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] E. London,et al. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. , 1998, Journal of medicinal chemistry.
[41] R. Traystman,et al. Cerebral Blood Flow in Primates Is Increased by Isoflurane over Time and Is Decreased by Nitric Oxide Synthase Inhibition , 1994, Anesthesiology.
[42] A. R. Banknieder,et al. Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). , 1978, Laboratory animal science.
[43] G. Saidel,et al. Iterative optimal design of PET experiments for estimating β-adrenergic receptor concentration , 2000, Medical and Biological Engineering and Computing.
[44] M. Quik,et al. Declines in Different β2* Nicotinic Receptor Populations in Monkey Striatum after Nigrostriatal Damage , 2002, Journal of Pharmacology and Experimental Therapeutics.
[45] Banknieder Ar,et al. Comparison of ketmine with the combination of ketamine and xylazine for effective anesthesia in the rhesus monkey (Macaca mulatta). , 1978 .
[46] D Wyper,et al. Nicotinic Acetylcholine Receptor Distribution in Alzheimer's Disease, Dementia with Lewy Bodies, Parkinson's Disease, and Vascular Dementia: In Vitro Binding Study Using 5-[125I]-A-85380 , 2004, Neuropsychopharmacology.
[47] T. Abbruscato,et al. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. , 2002, Journal of pharmaceutical sciences.
[48] G. J. Crystal,et al. Regional blood flow in canine brain during nicotine infusion: effect of autonomic blocking drugs. , 1983, Stroke.
[49] Edythe D London,et al. Graphical analysis of 2‐[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain , 2003, Synapse.
[50] N. Kassell,et al. Comparison of systemic and cerebrovascular effects of isoflurane and halothane. , 1984, Neurosurgery.
[51] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[52] J Delforge,et al. Experimental design optimisation: theory and application to estimation of receptor model parameters using dynamic positron emission tomography. , 1989, Physics in medicine and biology.
[53] D. Wieland,et al. Concentration of dopamine analogs in the adrenal medulla. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[54] N. Alpert,et al. Comparison of Two Compartmental Models for Describing Receptor Ligand Kinetics and Receptor Availability in Multiple Injection PET Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[55] R. Friedland,et al. PET quantification of specific binding of carbon-11-nicotine in human brain. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] Peter Herscovitch,et al. Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[57] F. Dollé,et al. Fluoro-A-85380 demonstrated no mutagenic properties in in vivo rat micronucleus and Ames tests. , 2002, Nuclear medicine and biology.
[58] R. Egleton,et al. Nicotine increases in vivo blood–brain barrier permeability and alters cerebral microvascular tight junction protein distribution , 2004, Brain Research.
[59] C. Gotti,et al. Human neuronal nicotinic receptors , 1997, Progress in Neurobiology.
[60] Agneta Nordberg,et al. Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by (±)-[3 H]epibatidine , 1998, Brain Research.
[61] D E Kuhl,et al. Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[62] S. Potkin,et al. Synthesis and evaluation of nicotine alpha4beta2 receptor radioligand, 5-(3'-18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)pyridine, in rodents and PET in nonhuman primate. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[63] C. Crouzel,et al. Characterization of the nicotinic ligand 2-[18F]fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine in vivo. , 1998, Life sciences.
[64] G Brix,et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[65] Edythe D London,et al. Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography , 2005, Journal of Pharmacology and Experimental Therapeutics.
[66] Marcel Ricard,et al. Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[67] C Crouzel,et al. Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[68] J M Links,et al. In vivo imaging of brain nicotinic acetylcholine receptors with 5-[123I]iodo-A-85380 using single photon emission computed tomography. , 1998, Life sciences.
[69] D. Marquardt. An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .
[70] J Delforge,et al. Concept of reaction volume in the in vivo ligand-receptor model. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[71] Lee W. Schruben,et al. Modeling & Analysis , 2003, NeuroImage.
[72] Bernard Bendriem,et al. Quantitation of Extrastriatal D2 Receptors Using a Very High-Affinity Ligand (FLB 457) and the Multi-Injection Approach , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[73] Y. Magata,et al. Evaluation of 5-11C-Methyl-A-85380 as an Imaging Agent for PET Investigations of Brain Nicotinic Acetylcholine Receptors , 2004 .
[74] H. Weiss,et al. Effects of isoflurane on transport across the blood-brain barrier. , 1992, Anesthesiology.